Restored expression levels of TET1 decrease the proliferation and migration of renal carcinoma cells

Fan,Min; He,Xiaozhou; Xu,Xianlin

doi:10.3892/mmr.2015.4058

Restored expression levels of TET1 decrease the proliferation and migration of renal carcinoma cells

Authors:
- Min Fan
- Xiaozhou He
- Xianlin Xu
View Affiliations

Affiliations: Department of Urology, The First People's Hospital of Changzhou, Changzhou, Jiangsu 213003, P.R. China
Published online on: July 8, 2015 https://doi.org/10.3892/mmr.2015.4058
Pages: 4837-4842
Copyright: © Fan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Renal carcinoma is the most common type of kidney cancer in adults and is responsible for ~90‑95% of the cases of kidney cancer. Ten‑eleven translocation methylcytosine dioxygenase 1 (TET1) is a member of the TET family of enzymes, and is expressed at low levels in multiple malignancies. In the present study, a series of experiments were designed and performed to investigate whether the expression of TET1 is clinically correlated with clinical outcomes in renal carcinoma, and to examine the associations between TET1 expression level and the proliferation and migration in renal carcinoma cells. As a result, TET1 was observed to exhibit markedly low expression levels in 54 tumor tissue samples from 54 patients with renal carcinoma. Furthermore, statistical analysis revealed a clinical correlation between low expression levels of TET1 and the prognosis of patients with renal carcinoma. When TET1 was overexpressed in renal carcinoma cells, the viability and invasive abilities of the cells were decreased, and the rate of apoptosis was increased. In conclusion, the results demonstrated that TET1 is involved in tumor inhibition in renal carcinoma by promoting cell apoptosis and inhibiting cell proliferation and invasion, which may be exploited as a novel therapeutic target in the treatment of renal carcinoma.

View Figures

View References

1	Naito S, Yamamoto N, Takayama T, Muramoto M, Shinohara N, Nishiyama K, Takahashi A, Maruyama R, Saika T, Hoshi S, et al: Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: A cooperative group report of 1463 patients. Eur Urol. 57:317–326. 2010. View Article : Google Scholar
2	Wang LL: Biology of osteogenic sarcoma. Cancer J. 11:294–305. 2005. View Article : Google Scholar : PubMed/NCBI
3	Shor AC, Keschman EA, Lee FY, Muro-Cacho C, Letson GD, Trent JC, Pledger WJ and Jove R: Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival. Cancer Res. 67:2800–2808. 2007. View Article : Google Scholar : PubMed/NCBI
4	Assouad J, Petkova B, Berna P, Dujon A, Foucault C and Riquet M: Renal cell carcinoma lung metastases surgery: Pathologic findings and prognostic factors. Ann Thorac Surg. 84:1114–1120. 2007. View Article : Google Scholar : PubMed/NCBI
5	Ono R, Taki T, Taketani T, Taniwaki M, Kobayashi H and Hayashi Y: LCX, leukemia-associated protein with a CXXC domain, is fused to MLL in acute myeloid leukemia with trilineage dysplasia having t (10;11) (q22;q23). Cancer Res. 62:4075–4080. 2002.PubMed/NCBI
6	Ito S, D'Alessio AC, Taranova OV, Hong K, Sowers LC and Zhang Y: Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature. 466:1129–1133. 2010. View Article : Google Scholar : PubMed/NCBI
7	Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y, Agarwal S, Iyer LM, Liu DR, Aravind L, et al: Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science. 324:930–935. 2009. View Article : Google Scholar : PubMed/NCBI
8	Guo JU, Su Y, Zhong C, Ming GL and Song H: Hydroxylation of 5-methylcytosine by TET1 promotes active DNA demethylation in the adult brain. Cell. 145:423–434. 2011. View Article : Google Scholar : PubMed/NCBI
9	Haffner MC, Chaux A, Meeker AK, Esopi DM, Gerber J, Pellakuru LG, Toubaji A, Argani P, Iacobuzio-Donahue C, Nelson WG, et al: Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers. Oncotarget. 2:627–637. 2011. View Article : Google Scholar : PubMed/NCBI
10	Yang H, Liu Y, Bai F, Zhang JY, Ma SH, Liu J, Xu ZD, Zhu HG, Ling ZQ, Ye D, et al: Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation. Oncogene. 32:663–669. 2013. View Article : Google Scholar
11	Lian CG, Xu Y, Ceol C, Wu F, Larson A, Dresser K, Xu W, Tan L, Hu Y, Zhan Q, et al: Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell. 150:1135–1146. 2012. View Article : Google Scholar : PubMed/NCBI
12	Fu HL, Ma Y, Lu LG, Hou P, Li BJ, Jin WL and Cui DX: TET1 Exerts its tumor suppressor function by interacting with p53-EZH2 pathway in gastric cancer. J Biomed Nanotechnol. 10:1217–1230. 2014. View Article : Google Scholar : PubMed/NCBI
13	Hsu CH, Peng KL, Kang ML, Chen YR, Yang YC, Tsai CH, Chu CS, Jeng YM, Chen YT, Lin FM, et al: TET1 suppresses cancer invasion by activating the tissue inhibitors of metalloproteinases. Cell Rep. 2:568–579. 2012. View Article : Google Scholar : PubMed/NCBI
14	Sun M, Song CX, Huang H, Frankenberger CA, Sankarasharma D, Gomes S, Chen P, Chen J, Chada KK, He C, et al: HMGA2/TET1/HOXA9 signaling pathway regulates breast cancer growth and metastasis. Proc Natl Acad Sci USA. 110:9920–9925. 2013. View Article : Google Scholar : PubMed/NCBI
15	Hou P, Ji M, Yang B, Chen Z, Qiu J, Shi X and Lu Z: Quantitative analysis of promoter hypermethylation in multiple genes in osteosarcoma. Cancer. 106:1602–1609. 2006. View Article : Google Scholar : PubMed/NCBI
16	Oh JH, Kim HS, Kim HH, Kim WH and Lee SH: Aberrant methylation of p14ARF gene correlates with poor survival in osteosarcoma. Clin Orthop Relat Res. 442:216–222. 2006. View Article : Google Scholar : PubMed/NCBI
17	Frycz BA, Murawa D, Borejsza-Wysocki M, Marciniak R, Murawa P, Drews M, Kołodziejczak A, Tomela K and Jagodziński PP: Decreased expression of ten-eleven translocation 1 protein is associated with some clinicopathological features in gastric cancer. Biomed Pharmacother. 68:209–212. 2014. View Article : Google Scholar : PubMed/NCBI
18	Sun M, Song CX, Huang H, Frankenberger CA, Sankarasharma D, Gomes S, Chen P, Chen J, Chada KK, He C, et al: HMGA2/TET1/HOXA9 signaling pathway regulates breast cancer growth and metastasis. Proc Natl Acad Sci. 110:9920–9925. 2013. View Article : Google Scholar : PubMed/NCBI
19	Ivanov M, Barragan I and Ingelman-Sundberg M: Epigenetic mechanisms of importance for drug treatment. Trends Pharmacol Sci. 35:384–396. 2014. View Article : Google Scholar : PubMed/NCBI
20	Jones PA and Laird PW: Cancer epigenetics comes of age. Nat Genet. 21:163–167. 1999. View Article : Google Scholar : PubMed/NCBI
21	Ito S, Shen L, Dai Q, Wu SC, Collins LB, Swenberg JA, He C and Zhang Y: Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science. 333:1300–1303. 2011. View Article : Google Scholar : PubMed/NCBI
22	Hou P, Ji M, Yang B, Chen Z, Qiu J, Shi X and Lu Z: Quantitative analysis of promoter hypermethylation in multiple genes in osteosarcoma. Cancer. 106:1602–1609. 2006. View Article : Google Scholar : PubMed/NCBI
23	Rao-Bindal K and Kleinerman ES: Epigenetic regulation of apoptosis and cell cycle in osteosarcoma. Sarcoma. 2011:6794572011. View Article : Google Scholar : PubMed/NCBI